Market Cap
US$26.7b
Last Updated
2020/02/23 01:18 UTC
Data Sources
Company Financials +
Executive Summary
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has DexCom's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DXCM's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
2.6%
DXCM
-1.3%
US Medical Equipment
-1.1%
US Market
1 Year Return
112.8%
DXCM
19.6%
US Medical Equipment
17.9%
US Market
Return vs Industry: DXCM exceeded the US Medical Equipment industry which returned 19.6% over the past year.
Return vs Market: DXCM exceeded the US Market which returned 17.9% over the past year.
Shareholder returns
| DXCM | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.6% | -1.3% | -1.1% |
| 30 Day | 24.5% | -0.03% | 1.4% |
| 90 Day | 28.4% | 5.8% | 6.9% |
| 1 Year | 112.8%112.8% | 20.6%19.6% | 20.3%17.9% |
| 3 Year | 271.0%271.0% | 79.2%74.2% | 47.8%38.3% |
| 5 Year | 379.5%379.5% | 115.2%92.6% | 71.9%53.0% |
Price Volatility Vs. Market
How volatile is DexCom's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
DexCom, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year3 weeks ago | Simply Wall St
Is DexCom (NASDAQ:DXCM) Using Debt Sensibly?1 month ago | Simply Wall St
Who Has Been Selling DexCom, Inc. (NASDAQ:DXCM) Shares?Valuation
Is DexCom undervalued compared to its fair value and its price relative to the market?
262.44x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DXCM ($291.25) is trading above our estimate of fair value ($96.81)
Significantly Below Fair Value: DXCM is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DXCM is poor value based on its PE Ratio (262.4x) compared to the Medical Equipment industry average (46.6x).
PE vs Market: DXCM is poor value based on its PE Ratio (262.4x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: DXCM is poor value based on its PEG Ratio (7.6x)
Price to Book Ratio
PB vs Industry: DXCM is overvalued based on its PB Ratio (30.2x) compared to the US Medical Equipment industry average (4.1x).
Next Steps
Future Growth
How is DexCom forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
34.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DXCM's forecast earnings growth (34.4% per year) is above the savings rate (1.7%).
Earnings vs Market: DXCM's earnings (34.4% per year) are forecast to grow faster than the US market (14.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: DXCM's revenue (16.5% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: DXCM's revenue (16.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DXCM's Return on Equity is forecast to be high in 3 years time (28%)
Next Steps
Past Performance
How has DexCom performed over the past 5 years?
-9.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DXCM has high quality earnings.
Growing Profit Margin: DXCM became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: DXCM has become profitable over the past 5 years, growing earnings by -9.2% per year.
Accelerating Growth: DXCM has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: DXCM has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.7%).
Return on Equity
High ROE: DXCM's Return on Equity (11.5%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is DexCom's financial position?
Financial Position Analysis
Short Term Liabilities: DXCM's short term assets ($2.0B) exceed its short term liabilities ($360.2M).
Long Term Liabilities: DXCM's short term assets ($2.0B) exceed its long term liabilities ($1.2B).
Debt to Equity History and Analysis
Debt Level: DXCM's debt to equity ratio (120.1%) is considered high.
Reducing Debt: DXCM's debt to equity ratio has increased from 3.3% to 120.1% over the past 5 years.
Balance Sheet
Inventory Level: DXCM has a high level of physical assets or inventory.
Debt Coverage by Assets: DXCM's debt is covered by short term assets (assets are 1.9x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DXCM is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: DXCM is profitable, therefore cash runway is not a concern.
Next Steps
Dividend
What is DexCom's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate DXCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate DXCM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DXCM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DXCM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DXCM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.6yrs
Average management tenure
CEO
Kevin Sayer (61yo)
5.1yrs
Tenure
US$9,554,123
Compensation
Mr. Kevin Ronald Sayer has been Executive Chairman of DexCom, Inc. since July 30, 2018. Mr. Sayer has been the Chief Executive Officer of DexCom, Inc. since January 5, 2015 and as its President since June ...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD9.55M) is about average for companies of similar size in the US market ($USD10.81M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 5.1yrs | US$9.55m | 0.11% $29.5m | |
| Executive VP | 2.4yrs | US$3.39m | 0.00097% $258.8k | |
| Executive Vice President of Strategy & Corporate Development | 7.5yrs | US$3.17m | 0.041% $10.9m | |
| Executive Vice President of Clinical Affairs | 11.9yrs | US$3.17m | 0.021% $5.5m | |
| Executive VP & Chief Commercial Officer | 5.1yrs | US$3.21m | 0.022% $6.0m | |
| Executive VP & CTO | 1.3yrs | no data | 0.11% $29.3m | |
| Senior Investor Relations Manager | 0yrs | no data | no data | |
| Senior VP | 3.2yrs | no data | 0.0048% $1.3m | |
| Senior Vice President of Human Resources | 3.6yrs | no data | 0.017% $4.5m | |
| Executive Vice President of Operations | 0.4yrs | no data | 0.035% $9.3m |
3.6yrs
Average Tenure
49yo
Average Age
Experienced Management: DXCM's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 5.1yrs | US$9.55m | 0.11% $29.5m | |
| Lead Independent Director | 4.3yrs | US$373.59k | 0.015% $4.1m | |
| Independent Director | 6.3yrs | US$318.00k | 0.051% $13.5m | |
| Independent Director | 17.4yrs | US$332.57k | 0.044% $11.8m | |
| Independent Director | 10.6yrs | US$339.85k | 0.096% $25.7m | |
| Independent Director | 10.3yrs | US$318.00k | 0.016% $4.3m | |
| Director | 0.4yrs | no data | no data | |
| Independent Director | 8.8yrs | US$318.00k | 0.012% $3.3m | |
| Independent Director | 2.9yrs | US$318.00k | 0.010% $2.7m |
6.3yrs
Average Tenure
61yo
Average Age
Experienced Board: DXCM's board of directors are considered experienced (6.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.3%.
Top Shareholders
Company Information
DexCom, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: DexCom, Inc.
- Ticker: DXCM
- Exchange: NasdaqGS
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$26.677b
- Shares outstanding: 91.59m
- Website: https://www.dexcom.com
Number of Employees
Location
- DexCom, Inc.
- 6340 Sequence Drive
- San Diego
- California
- 92121
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| DXCM | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Apr 2005 |
| DC4 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Apr 2005 |
| DXCM * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Apr 2005 |
Biography
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/23 01:18 |
| End of Day Share Price | 2020/02/21 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.